The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels

[1]  A. Carlsson,et al.  Attempts to measure endogenous levels of dopa and 5-hydroxytryptophan in rat brain , 2005, Journal of Neural Transmission.

[2]  F. Hirata,et al.  Formation of 5-hydroxykynurenine and 5-hydroxykynurenamine from 5-hydroxytryptophan in rabbit small intestine. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[3]  W. C. Purdy,et al.  Liquid chromatographic-fluorometric system for the determination of indoles in physiological samples. , 1979, Analytical chemistry.

[4]  G. Lees,et al.  Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase. , 1979, Molecular pharmacology.

[5]  G. Johnson,et al.  Radioenzymatic assay of DOPA (3,4-dihydroxyphenylalanine). , 1978, Clinical chemistry.

[6]  S. Young,et al.  A controlled study of tryptophan-benserazide in schizophrenia. , 1978, Communications in psychopharmacology.

[7]  R. Wurtman,et al.  Suppression of noradrenaline synthesis in sympathetic nerves by carbidopa, an inhibitor of peripheral dopa decarboxylase , 1977, Nature.

[8]  H. Baker,et al.  The determination of 5-hydroxytryptophan and its metabolites in plasma following administration to man. , 1976, Clinica chimica acta; international journal of clinical chemistry.

[9]  J. Korf,et al.  Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester. , 1976, Research communications in chemical pathology and pharmacology.

[10]  J. Warsh,et al.  Brain and peripheral metabolism of 5-hydroxytryptophan-14C following peripheral decarboxylase inhibition. , 1976, The Journal of pharmacology and experimental therapeutics.

[11]  J. Reid,et al.  Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition , 1974, Nature.